HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BANGALE, Y. Articles by PAUL, S. Search for Related Content PubMed PubMed Citation Articles by BANGALE, Y. Articles by PAUL, S.

VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease

Chemical Immunology Research Center, Departments of Pathology and Medicine, University of Texas Medical School, Houston, Texas, USA

¹Correspondence: Chemical Immunology Research Center, Department of Pathology, University of Texas Medical School, 6431 Fannin, Houston, TX 77030, USA. E-mail: Sudhir.Paul{at}uth.tmc.edu

The immunoregulatory neuropeptide vasoactive intestinal peptide (VIP) was cleaved by purified IgG from Fas-defective C3H/gld mice, lupus patients, and autoimmune thyroiditis patients. No VIPase activity was detected in IgG from control mice and humans. Kinetic analyses of VIPase IgG preparations suggested low-affinity recognition of VIP. Yet the VIPase activity was VIP selective, judged by lack of correlation with other protease activities expressed by the IgG and by noninterference of unrelated peptides in the activity. Recombinant Fv constructs selected from a human lupus phage show library displayed VIPase activity, confirming that the active site is located in the V domains. Inhibition of the VIPase activity by di-isopropylfluorophosphate suggested a serine protease-like mechanism of catalysis. Irreversible binding of a biotinyated phosphonate diester by the IgG and Fv preparations was observed, consistent with the presence of activated nucleophiles similar to those in enzymes capable of covalent catalysis. These observations show that VIP is a target for specific catalytic autoantibodies in autoimmune disease.—Bangale, Y., Karle, S., Planque, S., Zhou, Y.-X., Taguchi, H., Nishiyama, Y., Kalaga, L. L. R., Paul, S. VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease.

Key Words: SLE • neuroimmune regulation • catalytic antibodies

This article has been cited by other articles:

				E. Gonzalez-Rey, P. Anderson, and M. Delgado Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii70 - iii76. [Abstract] [Full Text] [PDF]

				A. Chorny, E. Gonzalez-Rey, A. Fernandez-Martin, D. Pozo, D. Ganea, and M. Delgado Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders PNAS, September 20, 2005; 102(38): 13562 - 13567. [Abstract] [Full Text] [PDF]

				D. POZO and M. DELGADO The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J, September 1, 2004; 18(12): 1325 - 1334. [Abstract] [Full Text] [PDF]

				S. Planque, Y. Bangale, X.-T. Song, S. Karle, H. Taguchi, B. Poindexter, R. Bick, A. Edmundson, Y. Nishiyama, and S. Paul Ontogeny of Proteolytic Immunity: IgM SERINE PROTEASES J. Biol. Chem., April 2, 2004; 279(14): 14024 - 14032. [Abstract] [Full Text] [PDF]

				Y. Nishiyama, G. Bhatia, Y. Bangale, S. Planque, Y. Mitsuda, H. Taguchi, S. Karle, and S. Paul Toward Selective Covalent Inactivation of Pathogenic Antibodies: A PHOSPHONATE DIESTER ANALOG OF VASOACTIVE INTESTINAL PEPTIDE THAT INACTIVATES CATALYTIC AUTOANTIBODIES J. Biol. Chem., February 27, 2004; 279(9): 7877 - 7883. [Abstract] [Full Text] [PDF]

				S. Paul, S. Planque, Y.-X. Zhou, H. Taguchi, G. Bhatia, S. Karle, C. Hanson, and Y. Nishiyama Specific HIV gp120-cleaving Antibodies Induced by Covalently Reactive Analog of gp120 J. Biol. Chem., May 23, 2003; 278(22): 20429 - 20435. [Abstract] [Full Text] [PDF]